INTRODUCTION: Two antitumor necrosis factor therapies (infliximab [IFX] and adalimumab [ADA]) have been approved for the treatment of pediatric Crohn's disease (CD) but have not been compared in head-to-head trials. The aim of this study was to compare the efficacy and safety of ADA and IFX by propensity score matching in a prospective cohort of pediatric patients with luminal CD and at least a 24-month follow-up. METHODS: Among 100 patients, 75 met the inclusion criteria, and 62 were matched by propensity score. We evaluated time to treatment escalation as the primary outcome and primary nonresponse, predictors of treatment escalation and relapse, serious adverse events, pharmacokinetics, and effect of concomitant immunomodulators as secondary outcomes. RESULTS: There was no difference between ADA and IFX in time to treatment escalation (HR = 0.63 [95% CI 0.31-1.28] P = 0.20), primary nonresponse (P = 0.95), or serious adverse events. The median (interquartile range) trough levels at the primary outcome were 14.05 (10.88-15.40) and 6.15 (2.08-6.58) µg/mL in the ADA and IFX groups, respectively. On a multivariate analysis, the combination of anti-Saccharomyces cerevisiae antibody negativity and antineutrophil cytoplasmic antibody positivity was a strong independent predictor of treatment escalation (HR 5.19, [95% CI 2.41-11.18], P < 0.0001). The simple endoscopic score for CD, L3 disease phenotype, and use of concomitant immunomodulators for at least the first 6 months revealed a trend toward significance on a univariate analysis. DISCUSSION: Propensity score matching did not reveal substantial differences in efficacy or safety between ADA and IFX. The anti-S. cerevisiae antibody negativity and antineutrophil cytoplasmic antibody positivity combination is a strong predictor of treatment escalation.

Gastroenterology and Nutrition Unit Department of Paediatrics 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

IBD Clinical and Research Centre ISCARE Prague Czech Republic

Zobrazit více v PubMed

Hyams J, Crandall W, Kugathasan S, et al. . Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863–6; quiz 1165-6. PubMed

Hyams JS, Griffiths A, Markowitz J, et al. . Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012;143:365–e2. PubMed

Hazlewood GS, Rezaie A, Borman M, et al. . Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: A network meta-analysis. Gastroenterology 2015;148:344–5, e5; quiz e14-5. PubMed

Li S, Reynaert C, Su AL, et al. . Efficacy and safety of infliximab in pediatric Crohn disease: A systematic review and meta-analysis. Can J Hosp Pharm 2019;72:227–38. PubMed PMC

Nuti F, Civitelli F, Bloise S, et al. Prospective evaluation of the achievement of mucosal healing with anti-TNF-alpha therapy in a paediatric Crohn's disease cohort. J Crohns Colitis 2016;10:5–12. PubMed

Nuti F, Viola F, Civitelli F, et al. . Biological therapy in a pediatric Crohn disease population at a referral center. J Pediatr Gastroenterol Nutr 2014;58:582–7. PubMed

Singh S, Fumery M, Sandborn WJ, et al. . Systematic review and network meta-analysis: First- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther 2018;48:394–409. PubMed

Singh S, Garg SK, Pardi DS, et al. . Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: A systematic review and network meta-analysis. Mayo Clin Proc 2014;89:1621–35. PubMed

Romeo AC, Ventimiglia M, Dipasquale V, et al. . Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian network. Clin Res Hepatol Gastroenterol 2020;44:223–9. PubMed

Ruemmele FM, Veres G, Kolho KL, et al. . Consensus guidelines of ecco/espghan on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179–207. PubMed

van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: An ECCO-ESPGHAN guideline update. J Crohns Colitis 2020. doi: 10.1093/ecco-jcc/jjaa161. PubMed DOI

Bank S, Andersen PS, Burisch J, et al. Effectiveness of anti-tumour necrosis factor-alpha therapy in Danish patients with inflammatory bowel diseases. Dan Med J 2015;62:A4994. PubMed

Cosnes J, Sokol H, Bourrier A, et al. . Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. Aliment Pharmacol Ther 2016;44:1102–13. PubMed

Kestens C, van Oijen MG, Mulder CL, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol 2013;11:826–31. PubMed

Lehtola E, Haapamaki J, Farkkila MA. Outcome of inflammatory bowel disease patients treated with TNF-alpha inhibitors: Two-year follow-up. Scand J Gastroenterol 2016;51:1476–81. PubMed

Liu J, Sylwestrzak G, Ruggieri AP, et al. . Intravenous versus subcutaneous anti-TNF-alpha agents for Crohn's disease: A comparison of effectiveness and safety. J Manag Care Spec Pharm 2015;21:559–66. PubMed PMC

Osterman MT, Haynes K, Delzell E, et al. . Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol 2014;12:811–e3. PubMed PMC

Patil SA, Rustgi A, Langenberg P, et al. . Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. Dig Dis Sci 2013;58:209–15. PubMed

Preda C, Fulger L, Gheorghe L, et al. . Adalimumab and infliximab in Crohn's disease–real life data from a national retrospective cohort study. Curr Health Sci J 2016;42:115–24. PubMed PMC

Varma P, Paul E, Huang C, et al. . A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease. Intern Med J 2016;46:798–804. PubMed

Yokoyama K, Yamazaki K, Katafuchi M, et al. . A retrospective claims database study on drug utilization in Japanese patients with Crohn's disease treated with adalimumab or infliximab. Adv Ther 2016;33:1947–63. PubMed PMC

Zorzi F, Zuzzi S, Onali S, et al. . Efficacy and safety of infliximab and adalimumab in Crohn's disease: A single centre study. Aliment Pharmacol Ther 2012;35:1397–407. PubMed

Doecke JD, Hartnell F, Bampton P, et al. . Infliximab vs. adalimumab in Crohn's disease: Results from 327 patients in an Australian and New Zealand observational cohort study. Aliment Pharmacol Ther 2017;45:542–52. PubMed

Narula N, Kainz S, Petritsch W, et al. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-alpha naive Crohn's disease. Aliment Pharmacol Ther 2016;44:170–80. PubMed

Benmassaoud A, Al-Taweel T, Sasson MS, et al. . Comparative effectiveness of infliximab versus adalimumab in patients with biologic-naive Crohn's disease. Dig Dis Sci 2018;63:1302–10. PubMed

Olivera P, Thiriet L, Luc A, et al. . Treatment persistence for infliximab versus adalimumab in Crohn's disease: A 14-year single-center experience. Inflamm Bowel Dis 2017;23:976–85. PubMed

Tursi A, Elisei W, Picchio M, et al. . Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres. Eur J Intern Med 2014;25:485–90. PubMed

Di Domenicantonio R, Trotta F, Cascini S, et al. Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clin Epidemiol 2018;10:203–13. PubMed PMC

Jung YS, Han M, Park S, et al. . Biologic use patterns and predictors for non-persistence and switching of biologics in patients with inflammatory bowel disease: A nationwide population-based study. Dig Dis Sci 2020;65:1436–44. PubMed

Ananthakrishnan AN, Cagan A, Cai T, et al. . Comparative effectiveness of infliximab and adalimumab in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2016;22:880–5. PubMed PMC

Kaniewska M, Rosołowski M, Rydzewska G. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease. Pol Arch Intern Med 2019;129:484–9. PubMed

Ma C, Huang V, Fedorak DK, et al. . Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study. J Crohns Colitis 2014;8:1454–63. PubMed

Riis A, Martinsen TC, Waldum HL, et al. . Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scand J Gastroenterol 2012;47:649–57. PubMed

Singh S, Heien HC, Sangaralingham LR, et al. . Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn's disease. Clin Gastroenterol Hepatol 2016;14:1120–96. PubMed PMC

Inokuchi T, Takahashi S, Hiraoka S, et al. . Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics. J Gastroenterol Hepatol 2019;34:1329–36. PubMed

Taxonera C, Robledo P, Rodríguez A. Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease. Rev Esp Enferm Dig 2017;109:690–3. PubMed

Gomollón F, Dignass A, Annese V, et al. . 3rd european evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis 2017;11:3–25. PubMed

Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci 2019;20:2529. PubMed PMC

Bronsky J, de Ridder L, Ruemmele FM, et al. . Diagnostic and therapeutic approach in paediatric inflammatory bowel diseases: Results from a clinical practice survey. J Pediatr Gastroenterol Nutr 2019;68:676–83. PubMed

Penagini F, Cococcioni L, Pozzi E, et al. . Biological therapy in pediatric age. Pharmacol Res 2020;161:105120. PubMed

Mogilevski T, Sparrow MP. Infliximab versus adalimumab in patients with biologic-naive Crohn's disease: Is the difference real? Dig Dis Sci 2018;63:1094–6. PubMed

Srinivas NR. Letter: Comparative safety and efficacy of infliximab vs Adalimumab in Crohn's disease–should one consider disease location? Aliment Pharmacol Ther 2016;44:771–2. PubMed

Tursi A, Elisei W, Picchio M, et al. . Letter: Infliximab vs. adalimumab in treating ambulatory perianal fistulising Crohn's disease. Aliment Pharmacol Ther 2014;40:218–20. PubMed

van Rheenen H, van Rheenen PF. Long-term efficacy of anti-tumor necrosis factor agents in pediatric luminal Crohn's disease: A systematic review of real-world evidence studies. Pediatr Gastroenterol Hepatol Nutr 2020;23:121–31. PubMed PMC

Qiu Y, Chen BL, Mao R, et al. Systematic review with meta-analysis: Loss of response and requirement of anti-TNFalpha dose intensification in Crohn's disease. J Gastroenterol 2017;52:535–54. PubMed

Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: From basic science to clinical practice. J Crohns Colitis 2020;14:694–709. PubMed

Ricciuto A, Aardoom M, Orlanski-Meyer E, et al. . Predicting outcomes in pediatric Crohn's disease for management optimization: Systematic review and consensus statements from the pediatric inflammatory bowel disease-ahead program. Gastroenterology 2021;160:403–36.e26. PubMed

Kugathasan S, Denson LA, Walters TD, et al. . Prediction of complicated disease course for children newly diagnosed with Crohn's disease: A multicentre inception cohort study. Lancet 2017;389:1710–8. PubMed PMC

Caviglia GP, Rosso C, Stalla F, et al. . On-treatment decrease of serum interleukin-6 as a predictor of clinical response to biologic therapy in patients with inflammatory bowel diseases. J Clin Med 2020;9:800. PubMed PMC

Gole B, Potočnik U. Pre-treatment biomarkers of anti-tumour necrosis factor therapy response in Crohn's disease-a systematic review and gene ontology analysis. Cells 2019;8:515. PubMed PMC

Mateos B, Saez-Gonzalez E, Moret I, et al. Plasma oncostatin-m, TNF-alpha, IL-7 and IL-13 network predicts Crohn's disease response to infliximab, as assessed by calprotectin log-drop. Dig Dis 2020;39:1–9. PubMed

Salvador-Martin S, Bossacoma F, Pujol-Muncunill G, et al. Genetic predictors of long-term response to antitumor necrosis factor agents in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2020;71:508–15. PubMed

Xu L, Shen J, Zheng Q. Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn's disease. Int J Colorectal Dis 2020;35:2019–26. PubMed

Zorlu O, Bülbül Başkan E, Yazici S, et al. . Predictors of drug survival of biologic therapies in psoriasis patients. J Dermatolog Treat 2020;33:437–42. PubMed

Mocko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis. Pharmacol Rep 2016;68:1237–43. PubMed

Ruemmele FM. Safety of anti-TNF biologics in paediatric inflammatory bowel disease. Lancet Gastroenterol Hepatol 2019;4:813–5. PubMed

Wintzell V, Svanström H, Melbye M, et al. . Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: A nationwide cohort study. Lancet Gastroenterol Hepatol 2019;4:845–53. PubMed

Santacana E, Rodríguez-Alonso L, Padullés A, et al. . Predictors of infliximab trough concentrations in inflammatory bowel disease patients using a repeated-measures design. Ther Drug Monit 2020;42:102–10. PubMed

Church PC, Hyams J, Ruemmele F, et al. . The continental divide: Anti-TNF use in pediatric IBD is different in north America compared to other parts of the world. Can J Gastroenterol Hepatol 2018;2018:3190548. PubMed PMC

Peyrin-Biroulet L, Salleron J, Filippi J, et al. Anti-TNF monotherapy for Crohn's disease: A 13-year multicentre experience. J Crohns Colitis 2016;10:516–24. PubMed PMC

Colombel JF, Sandborn WJ, Reinisch W, et al. . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383–95. PubMed

Dhillon AS, Harris AW. Infliximab vs adalimumab for Crohn's disease. Clin Gastroenterol Hepatol 2015;13:210. PubMed

Osterman MT. Reply: To PMID 23811254. Clin Gastroenterol Hepatol 2015;13:210–1. PubMed

Matsumoto T, Motoya S, Watanabe K, et al. . Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: A prospective, randomized trial. J Crohns Colitis 2016;10:1259–66. PubMed

Aliyev ER, Hay JW, Hwang C. Cost-effectiveness comparison of ustekinumab, infliximab, or adalimumab for the treatment of moderate-severe Crohn's disease in biologic-naive patients. Pharmacotherapy 2019;39:118–28. PubMed

Choi GK, Collins SD, Greer DP, et al. . Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. J Crohns Colitis 2014;8:375–83. PubMed

Sussman DA, Kubiliun N, Mulani PM, et al. . Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (compairs). Inflamm Bowel Dis 2012;18:2043–55. PubMed

Yu AP, Johnson S, Wang ST, et al. . Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics 2009;27:609–21. PubMed

Rencz F, Gulácsi L, Péntek M, et al. . Cost-utility of biological treatment sequences for luminal Crohn's disease in europe. Expert Rev Pharmacoecon Outcomes Res 2017;17:597–606. PubMed

Cozijnsen MA, Samsom JN, de Ridder L. Anti-tumour necrosis factor therapy for paediatric Crohn's disease: Improved benefits through treatment optimisation, deeper understanding of its risks, and reduced costs due to biosimilar availability. Paediatr Drugs 2018;20:19–28. PubMed PMC

Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: An open-label multicentre randomised controlled trial. Gut 2020;71:34–42. PubMed PMC

Sustainability of biologic treatment in paediatric patients with Crohn's disease: population-based registry analysis